Skip to main content
. 2023 Feb 7;24(4):3323. doi: 10.3390/ijms24043323
T2DM type 2 diabetes mellitus
NAFLD non-alcoholic fatty liver disease
CHD coronary heart disease
MetS metabolic syndrome
IGT Impaired Glucose Tolerance
PCOS Polycystic ovary syndrome
FBG fasting blood glucose
HbA1c hemoglobin A1c
TC total cholesterol
TG triglycerides
FINS fasting insulin
LDL-C low density lipoprotein cholesterol
HDL-C high density lipoprotein cholesterol
Non-HDL-C non-high density lipoprotein cholesterol
VLDL-C very-low-density lipoprotein cholesterol
HDL high density lipoprotein
HOMA-β homeostasis model assessment β
HOMA-IR homeostasis model assessment-insulin resistance
ISI insulin sensitivity index
QUICKI Quantitative Insulin Sensitivity Check Index
ALT alanine aminotransferase
AST aspartate aminotransferase
8-OHdG 8-Hydroxy-2′-deoxyguanosine
CML carboxy methyl lysine
BMI body mass index
BW body weight
WC Waist circumference
TNF-α tumor necrosis factor-α
FFA free fatty acid
CRP C-reactive protein
hs-CRP high sensitivity C-reactive protein
IL-6 interleukin-6
SOD superoxide dismutase
MDA malonaldehyde
LP(a) lipoprotein(a)
MCP-1 macrophage chemoattractant protein-1
GSH glutathione
TAC total antioxidant capacity
PAB pro-oxidant–antioxidant balance
PWV pulse wave velocity
SUA serum uric acid
γ-GTP γ-glutamyl transpeptidase
2hpp 2-h postprandial glucose
IL-1β interleukin-1β
IL-4 interleukin-4
VEGF vascular endothelial growth factor
ox-LDL oxidized low density lipoprotein
LPL lipoprotein lipase
PPAR-γ peroxisome proliferator-activated receptor
GOT glutamic oxaloacetic transaminase
GPT glutamate pyruvate transaminase
GRAS generally recognized as safe
AGEs advanced glycosylation end products
Cmax maximum concentration